TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it will present data from its Phase I trial of EPC2407 at the 44th Annual Meeting of the American Society for Clinical Oncology (ASCO), taking place May 30 to June 3, 2008 in Chicago. EPC2407 is EpiCept’s novel small molecule vascular disruption agent (VDA) and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas.
